Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.390
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
2.450
+0.060 (2.51%)
After-hours: May 22, 2026, 7:57 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,492,353
Market Cap
12.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Theriva Biologics | 16 |
| Ernexa Therapeutics | 7 |
| Intensity Therapeutics | 7 |
| Phio Pharmaceuticals | 6 |
| Hoth Therapeutics | 3 |
| Cyclerion Therapeutics | 1 |
| GT Biopharma | 1 |
MBRX News
- 1 day ago - Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - GlobeNewsWire
- 7 days ago - Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewsWire
- 8 days ago - Moleculin Biotech Quarterly report: Q1 2026 - Filings
- 8 days ago - Moleculin Biotech Earnings release: Q1 2026 - Filings
- 9 days ago - Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30 - TheFly
- 9 days ago - Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks - GlobeNewsWire
- 10 days ago - Moleculin announces publication on cardiac safety profiloe of annamycin - TheFly
- 10 days ago - Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits - GlobeNewsWire